Delivery Order SPE2DB22D1202-SPE2DB25FVHY6
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain issued a delivery order valued at $35,355.44 to AmerisourceBergen Drug Corp on July 7, 2025. This competitively awarded, firm fixed-price delivery order, classified as non-set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery order is for pharmaceutical products and medical supplies to support federal medical procurement needs, with...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $17,056.07 to AmerisourceBergen Drug Corp on August 25, 2025, with completion expected by August 26, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $11,024.40 to AmerisourceBergen Drug Corp on September 8, 2025, for pharmaceutical and medical supply products under contract number 4569359419. This firm fixed-price delivery order, with an ultimate completion date of September 9, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was made through open competition with no set-aside...
- The U.S. Defense Logistics Agency, through its Medical Supply Chain division, awarded a delivery order valued at $81,150.96 to AmerisourceBergen Drug Corp on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The order will be performed at the company's corporate office...
- AmerisourceBergen Drug Corp was awarded a delivery order contract valued at $10,873.56 by the Defense Logistics Agency's Medical Supply Chain on August 11, 2025. This firm fixed-price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery order will be performed at AmerisourceBergen's corporate office location in...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $4,216.30 to AmerisourceBergen Drug Corp on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award represents a pharmaceutical delivery to be...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $10,181.21 by the Defense Logistics Agency's Medical Supply Chain on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The order will be fulfilled from the contractor's Corporate Office location in Conshohocken,...
- The Defense Logistics Agency's Medical Supply Chain awarded a $13,650.00 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, with completion scheduled for August 25, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The prime pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,054.44 to AmerisourceBergen Drug Corp for AMLOD-VALSA-HCTZ 10-320-25 MG 30S, a pharmaceutical product, on March 12, 2025, with completion expected by March 13, 2025. This competitively awarded, firm fixed-price contract was issued without set-aside status and will be performed at the vendor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $21,197.66 to AmerisourceBergen Drug Corp on August 9, 2025, with completion scheduled for August 11, 2025. This firm fixed-price, non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The delivery order will be performed at the contractor's corporate...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVHY6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,401.50 to AmerisourceBergen Drug Corp for pharmaceutical supplies, specifically AMLOD-VALSA-HCTZ 10-320-25 MG in a 30-count supply. This firm fixed-price delivery order, issued on August 21, 2025, with an ultimate completion date of August 22, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is part of AmerisourceBergen's comprehensive pharmaceutical supply relationship with the Defense Logistics Agency, which includes a prime IDV valued at $999,999,999.00 running through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen supplies a broad range of medications and medical commodities to support military and veteran healthcare systems. The parent IDC enables the company to fulfill federal medical procurement requirements across multiple therapeutic domains, including diabetes medications, neurological treatments, pain management pharmaceuticals, and other specialized healthcare products for customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 8/21/25 |